Member Info for RayPointer

THE CAPS LOCK KID IS BACK 😂

Hardly AI 😂

Double midprice = (Ask + Bid) / 2;

if (saleprice > midprice)

Essential: the ability to make paper aeroplanes out of LOIs

I thought Ambrose had plans to float in Outer Mongolia

I'm dead scared of being fomophobic

So how much experience have the 3 amigos of running a small biotech?

Zero I suspect.

So are they merely proposed just to keep an eye on Suzy and nothing else?

I think you will find it was Vulpes and not Redmile who were issued shares at 5p.

I stand to be corrected.

PM, you need a little more than good business people to make this company a success.

You also need an exceptional scientist of group of scientists to:

a) pick the possible winners (Suzy is doing OK at this)

b) see the product through to the end of the pre-clinical stage (so CLX is proving difficult in this respect, do we have

confidence in Suzy sorting out the problems?)

c) be proactive in improving the product (no sign of this happening for any of the products)

d) be skilled at evergreening a product such as 201 that is nearing the end of its patent period (no sign of this happening)

e) be inventive on how clinical trials should be designed (no news in this area for 201 in particular, combination trials are all the rage but no sign of Suzy testing products in combination with other agents)

f) be raising the profile of the pipeline by attending scientific conferences thereby bringing the products to the notice of big pharma (no sign of this happening)

g) finally the virtual absence of peer reviews does not inspire confidence

So, my question would be:

"Even if you had great business people in the company, would the science end up as being good enough to attract real deals?"

Requisition notice number 1 contained the following:

"The Company is seeking legal advice as to the validity of the requisition notice and a further announcement will be made in due course."

No such sentence in this latest Requisition Notice.

Hopefully this is a good sign that the people submitting the revised notice have not left room for Suzy to wriggle out of calling an EGM this time.

Using a place name as a verb is a novel use of English 😂

Purely IMHO, there is no correlation between the conferences Lindy attends and the release of trial results.

Stay cool and patient 😎

Drac

re "Melanoma Orphan status fast tracked drug"

Surely you must be aware that , as a long term holder, SCIB1 also has FDA Orphan status

https://www.scancell.co.uk/scib1-granted-fda-orphan-drug-status

Point taken Drac, but one school of thought would be that the current market plays into the hands of the LTSHs.

Of course, that's if you think that the Scope trial results later in the year will lead to a high probability of a deal.

Just when such a deal arrives is anyone's guess.

Remember that we are also promised the preliminary data from the Modi1 + 2CPIs cohorts later this year.

Not to mention the possibility of another Glycans deal or two.

Let the market do what markets do, and let us LTSHs do what we consider best on an individual by individual basis

It's worth just reiterating just how well the Scope trial is going from the 17th Jan RNS

"Exceptional results from the first 13 patients receiving SCIB1 in the ongoing SCOPE trial, with an objective response rate of 85%, indicate a high probability of success in this cohort which should complete in Q2 2024. Recruitment into the iSCIB1+ cohort is expected to be complete by the end of Q2 2024, with early data expected in Q3 2024."

"Prof Lindy Durrant, Chief Executive Officer, Scancell, commented: "Thanks to the excellent work done by the Scancell team, working hand in hand with a responsive MHRA, we are pleased to report today that we have received approval to include a third cohort of patients in the SCOPE trial who will now receive iSCIB1+ in combination with doublet checkpoints. We anticipate that iSCIB1+ will be as effective as SCIB1 and, with its potentially increased potency and broader patient profile, make it a promising candidate for registration studies. We look forward to providing further updates on our progress given the extremely positive results to date.""

https://www.lse.co.uk/rns/SCLP/update-on-scope-trial-xyrhx622822790d.html

If there are any developments with either the lab or the products, they would issue an RNS

"Its from April last year..."

but as stated in the article

"Updated on February 19, 2024"

Yes, the summary for Scancell is disappointing and not up-to-date.

Also, it even fails to correctly list the types of cancers that Modi1 is treating.

"The vaccine aims to treat melanoma, ovarian, lung, pancreatic and breast cancer."

Oh no, another comma missed out 😒

Can I have detention please rather than writing lines?

You sound like a fellow Burnley fan magnet 😂